Acorda Therapeutics Inc Net Income per Employee (ACORQ), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Acorda Therapeutics Inc   (ACORQ)
 

Acorda Therapeutics Inc Net Income per Employee

ACORQ's Quarterly Results, Trends, Rankings, Statistics
Acorda Therapeutics Inc recorded a cumulative net loss of $-263 million during 12 month ending in the first quarter 2024.
The Healthcare sector has seen employees of 60 other companies achieving higher income per employee. While Acorda Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 0 to 3803.


What is Income per Employee Ratio?






ACORQ Net Income per Employee (Mar 31 2024)
I. Quarter
(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -2,582,598 -2,478,961 -156,382 -205,069 -570,765
ACORQ's Total Ranking # 3803 # 0 # 0 # 0 #
Seq. Net Income Change - - - - -


ACORQ Net Income per Employee Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 61
Healthcare Sector # 562
Overall Market # 3803

Net Income per Employee Statistics
High Average Low
$ 1,404,127 $ -610,144 $ -2,676,137
(Sep 30 2013)   (Dec 31 2019)







Companies with similar Income per Employee for 12 month ending Mar 31 2024, within Healthcare Sector Income per Employee Income 12 month ending Mar 31 2024Number of Employees Mar 31 2024


Date modified: 2026-08-29T17:28:08+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.